The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Self-citationAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Cited by
Alley, E. W., Lopez, J., Santoro, A., Morosky, A., Saraf, S., Piperdi, B., & van Brummelen, E. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30169-9 · Cited by 490
Kindler, H. L., Ismaila, N., Armato, S. G., Bueno, R., Hesdorffer, M., Jahan, T., Jones, C. M., Miettinen, M., Pass, H., Rimner, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6394 · Cited by 420
Self-citationThe Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li, G., Tian, Y., & Zhu, W.-G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 352
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 337
Metadata
- Authors
- Krug, L. M., Kindler, H. L., Calvert, H., Manegold, C., Tsao, A. S., Fennell, D., Öhman, R., Plummer, R., Eberhardt, W. E. E., Fukuoka, K., Gaafar, R. M., Lafitte, J.-J., Hillerdal, G., Chu, Q., Buikhuisen, W. A., Lubiniecki, G. M., Sun, X., Smith, M., & Baas, P.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 16
- Issue
- 4
- Pages
- 447-456
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2169012257
- Cited by
- 215
- References
- 3
- FWCI
- 18.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(15)70056-2
- The paper
- Krug, L. M., Kindler, H. L., Calvert, H., Manegold, C., Tsao, A. S., Fennell, D., Öhman, R., Plummer, R., Eberhardt, W. E. E., Fukuoka, K., Gaafar, R. M., Lafitte, J.-J., Hillerdal, G., Chu, Q., Buikhuisen, W. A., Lubiniecki, G. M., Sun, X., Smith, M., & Baas, P. (2015). Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)70056-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.